Genocea Biosciences, Inc.

Children's Medical Center Corporation

Antigenics, Inc.

Jessica Baker Flechtner

Todd Michael Gierahn

Mojca Skoberne

Deborah Long

George Rainer Siber

Richard Malley

Paul Slusarewicz

Sunil Mehta

Pamela M Carroll

Hubert Lam

Kenya Prince-Cohane

Lisa K McNeil

Sofija Andjelic

Marie Lossky-Elias

Wendy Jane Broom

Brian H Barber

Methods and compositions for identifying antigens of human lymphocytes are provided herein.

Antigen screening system

Methods and compositions for identifying tumor antigens of human lymphocytes, and for identifying subjects for cancer therapy, are provided herein.

Treatment methods

Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.

Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. Highly effective vaccines and immunogenic compositions against HSV-2, which can be used therapeutically or prophylactically, are described.

is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions inthat contain fusion proteins. The antigens may be used therapeutically or prophylactically.

[object Object]

Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. Highly effective vaccines and immunogenic compositions against HSV-2 which can be used therapeutically or prophylactically, are described.

Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Hybrid antigens comprising at least one antigenic domain, at least one heat shock protein binding domain, and at least one improved peptide linker there between are described which are useful for the induction of an immune response to the antigenic domain when administered alone or in a complex with at least one heat shock protein. The hybrid antigens and complexes can be used to treat infectious diseases and cancers that express an antigen of the antigenic domain.

Growing community of inventors

Sudbury, MA, United States of America

Jessica Baker Flechtner